Edition:
United States

GeneNews Ltd (GNWSF.PK)

GNWSF.PK on OTC Markets Group

0.33USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$0.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,768
52-wk High
$0.53
52-wk Low
$0.01

Summary

Name Age Since Current Position

James Howard-Tripp

2013 Executive Chairman of the Board

Leslie Auld

2013 Chief Financial Officer, Treasurer, Director

Karl Wassmann

2011 Executive Vice President - US Corporate Development

Heinrich Dreismann

62 2013 Lead Director

Harry Glorikian

2008 Independent Director

Garth MacRae

81 2000 Independent Director

Rory Riggs

62 2013 Independent Director

Biographies

Name Description

James Howard-Tripp

Mr. James R. Howard-Tripp is Executive Chairman of the Board of GeneNews Ltd. Mr. Howard-Tripp, who joined the GeneNews Board in 2002, has specialized in the research, development and launch of innovative pharmaceutical products and the growth and development of the companies that research and market them. He has been involved in the management (GD Searle, Wyeth-Ayerst) and creation (Allelix, Labopharm, Dermacor) of several companies. Mr. Howard-Tripp has 13 years' experience as a President and CEO and has sat on multiple Boards, most as Chairman. Most recently, as President and CEO of Labopharm, he oversaw the research, development and approval of 3 products and the launch of 2, with the lead product marketed in 19 countries. Additionally, he has served on various scientific and industry committees as well as several not-for-profit boards.

Leslie Auld

Ms. Leslie Auld is Chief Financial Officer, Treasurer, Director of GeneNews Ltd. She has been appointed to the position of Director of the Company with effect from June 28, 2013. Ms. Auld began her professional career in 1991 with PriceWaterhouseCoopers. She later joined Helix BioPharmaCorp. where she progressed from Controller to Chief Financial Officer. In 2004, she joined Luminex Diagnostics (formerly TM BioScience Corp.) as Senior Director of Finance, where she focussed on finance and operations during a period of growth and then held a pivotal role in the transaction that took TM BioScience private when it was acquired by Luminex. Ms. Auld joined Attwell Capital Inc. (formerly Fralex Therapeutics) as Chief Financial Officer in 2007. She left that position in June 2009 but continued to support Attwell and other issuers in a consulting capacity. Ms. Auld was initially retained by GeneNews on January 1, 2010, as a financial consultant. A Chartered Accountant, Ms. Auld graduated with an Honours Bachelor of Science, Pharmacology & Toxicology from the University of Western Ontario, and has a Master of Business Administration degree from the University of Toronto.

Karl Wassmann

Heinrich Dreismann

Dr. Heiner Dreismann, Ph.D., is Lead Director of GeneNews Limited. He is the former President and CEO of Roche Molecular Systems (RMS), a division of F. Hoffmann-La Roche Ltd. and the company that pioneered molecular diagnostics in the clinical diagnostic arena. Dr. Dreismann led the introduction of polymerase chain reaction-based tests in Europe as early as 1992 and witnessed first hand the industry growth over the last two decades. During his tenure as CEO, RMS annual sales increased strongly and the portfolio of tests and hardware sales were greatly expanded. Prior to being appointed CEO, Dr. Dreismann held other senior positions within Roche Diagnostics in the areas of Global Business Development, Business Unit Manager for Polymerase Chain Reaction and Microbiology, as well as R&D positions in microbiology and infectious diseases, and in manufacturing. In addition, Dr. Dreismann serves as a director of several privately held and publicly traded health-care companies.

Harry Glorikian

Mr. Harry A. Glorikian is an Independent Director of GeneNews Limited., since April 2008. He heads Scientia Advisors with 20 years of experience in the healthcare and life science industries. He is known worldwide as a leader in helping companies streamline their operations and accelerate their growth. Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Mr. Glorikian has a deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia’s sophisticated framework and proprietary analytic tools. A sought-after speaker, Mr. Glorikian has addressed the National Institutes of Health, Molecular Medicine Tri-Conference and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, the Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine and many other media outlets. Harry holds an MBA from Boston University and a BA in Biology from San Francisco State University. He serves on many advisory boards and is an avid inventor who has several patents and patents pending in the US and abroad.

Garth MacRae

Mr. Garth A.C. MacRae is an Independent Director of GeneNews Limited. He is a Director of Dundee Corporation, a merchant bank and financial services company, since 1991. Mr. MacRae is a Chartered Accountant, having received his designation in Manitoba in 1957 and has been a member of the Ontario Institute of Chartered Accountants since 1970. In addition to being a Director of GeneNews and of Dundee Corporation, Mr. MacRae is a director of a number of other public and private companies.

Rory Riggs

Mr. Rory B. Riggs is an Independent Director of GeneNews Limited. He is the Managing Member of Balfour LLC, an investment management company. Mr. Riggs is the past President of Biomatrix, Inc., a NYSE listed company which developed and marketed one of the viscosupplementation products in the United States, Synvisc®, for the treatment of osteoarthritis. Prior to Biomatrix, Mr. Riggs was Chief Executive Officer of RF&P Corporation and was also a Managing Director of PaineWebber Inc. He holds a B.A. from Middlebury College, Vermont, and an MBA from the Graduate School of Business, Columbia University, New York.

Basic Compensation

Name Fiscal Year Total

James Howard-Tripp

438,216

Leslie Auld

269,361

Karl Wassmann

343,886

Heinrich Dreismann

249,369

Harry Glorikian

--

Garth MacRae

--

Rory Riggs

--
As Of  30 Dec 2014